Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLUO5K)

• Drug Name: BIIB094 Drug Info
• Synonyms: ION859

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMLUO5K

Molecule-Related Drug Atlas

Drug(s) Targeting Leucine-rich repeat kinase 2 (LRRK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DNL151	DMZT89C	Parkinson disease	8A00.0	Phase 1	[3]
DNL201	DMFEORD	Parkinson disease	8A00.0	Phase 1	[3]
Pyrrolo-pyridine derivative 2	DMVNY5I	N. A.	N. A.	Patented	[4]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[4]
Oxindole derivative 3	DM0ENF3	N. A.	N. A.	Patented	[4]
Aminopyridine derivative 3	DMSLJE8	N. A.	N. A.	Patented	[4]
Fused thiophene derivative 1	DMV7IX4	N. A.	N. A.	Patented	[4]
Oxindole derivative 4	DM3U58I	N. A.	N. A.	Patented	[4]
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[4]
Pyrrolo-pyrimidine derivative 8	DMZH27I	N. A.	N. A.	Patented	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leucine-rich repeat kinase 2 (LRRK2)	TTK0FEA	LRRK2_HUMAN	Inhibitor	[2]
Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA)	TT1HI8U	LRRK2_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03976349) A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Ionis
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.